Stock market today: S&P 500 hits fresh record close on stronger economic growth
Curanex Pharmaceuticals Inc. (CURX) completed its initial public offering on August 27, 2025, selling 3.75 million shares at $4.00 per share for gross proceeds of $15 million before underwriting fees and expenses.
The developmental stage pharmaceutical company’s shares began trading on the Nasdaq Capital Market on August 26, 2025. Curanex granted underwriters a 45-day option to purchase up to 562,500 additional shares at the offering price, less underwriting discounts.
Dominari Securities LLC served as lead underwriter, with Pacific Century Securities LLC and Revere Securities LLC as co-underwriters for the firm commitment offering. The Securities and Exchange Commission declared the company’s registration statement effective on August 12, 2025.
Based in Jericho, New York, Curanex focuses on developing botanical drugs for inflammatory diseases. The company’s lead candidate, Phyto-N, is a botanical extract that the company states has been used to treat patients with inflammatory diseases in China for 30 years.
According to the press release, Curanex has tested Phyto-N in animal models for six inflammatory conditions: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company identifies moderate to severe ulcerative colitis as its primary indication.
Curanex plans to advance Phyto-N through FDA-required studies, IND submission, and Phase I clinical trials. The information is based on a company press release statement.